STERIS plc (STE) continues to be a potentially undervalued
dividend stock despite earning a 'Strong Buy' rating upgrade and gaining a favorable endorsement from Jim Cramer, who named the health care sterility solutions provider a 'just a strong company'. The company's
performance is projected to benefit from strategic acquisitions amidst macroeconomic challenges and its continued recovery from a previous period of instability. Upcoming Q4 fiscal year 2025 financial results to be made public on May 15, 2025 are highly anticipated. Despite concerns about
shareholder returns because of higher share prices, recent earnings results suggest revenue growth and stable earnings per share (EPS). The company managed to beat forecasts with a Q3 revenue of $1.4 billion and an adjusted EPS of $2.32. Furthermore,
STERIS' restructuring plans, including selling its renal care business and dental segment, aim to streamline their operations. However, STERIS plc did face certain headwinds with CEO succession and layoffs as part of the restructuring process.
Steris Plc STE News Analytics from Wed, 24 Jun 2015 07:00:00 GMT to Sat, 26 Apr 2025 21:55:34 GMT -
Rating 6
- Innovation -4
- Information 7
- Rumor -6
